The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The public Consultation ends on Friday I think and it's possible a draft recommendation will be made but not officially published until July.
If it becomes clear it's not a FULL recommendation - and I take Muminr's points on board that NICE seem to be indicating it will be FULL - then it will be a bad weekend for share holders here. That might in fact precipitate GDR going private or being sold on the cheap. I think for now though Cheek doesn't want to go down that route. He appears to want to be rid of RF and get funding through other means and get the FDA partner announced asap. Someone's already said it, chicken and egg. IMO it's all hanging on this next bit of news from NICE. Hopefully it's good. If it is then sp should fly.
What’s happening Friday apart from it’s payday for most as the last Friday of the month?
Roger , I have given up on you :-) , good luck .
CYP2c19 kit is bigger than you think , it will get full recommendation, GDR has bigger plans than these 2 tests .. I will try to gather more data ..
https://www.nice.org.uk/news/article/nice-launches-second-consultation-on-genetic-testing-to-guide-treatment-after-a-stroke
Https://www.genomicseducation.hee.nhs.uk/blog/post-stroke-and-mini-stroke-prescribing-comments-sought-by-nice/
Personalised care to thousands’
Genomic testing can show if a patient carries one of the CYP2C19 variants that affects if clopidogrel will work well for them. “Recommending a genetic test that can offer personalised care to thousands of people who have a stroke each year will be a step forward in ensuring people receive the best possible treatment,” said NICE’s chief medical officer Professor Jonathan Benger. The Stroke Association’s chief executive Juliet Bouverie added: “Getting on the right medication and taking it as advised can really go far to prevent further strokes.” She also emphasised that patients who have not had a genomic test should not assume that their current medication isn’t working: “If you have been prescribed clopidogrel, you need to keep taking it. If you’re worried about your risk of another stroke, you should speak to your doctor.”
NICE’s consultation in genomic testing for patients who have had an ischaemic stroke has highlighted how point-of-care pharmacogenomic testing is entering the clinic. If you’re a pharmacist or a pharmacy technician who wants to learn how genomics is impacting your work, then check out this free eLearning tutorial into pharmacogenomics.
And roger M did not come to a neg conclusion , can you read his post again ..
Roger Please be informed you are not a grown up at all , hence you keep avoid the reasoning of why would some research a share after they have lost a fortune ...
It is clear you are trying to mislead us ..bad karma .. and it wont work .
we all know who are invested once this get nice full improvement .. this is going to rocket and yes you missed the boat .. please stop posting ...your rubbish .. give us facts please so we can help each other as a team , not rubbish ..
Thanks for a grown up post muminr . I’m glad I’m not the only one that waded through the whole discourse and came to a negative conclusion. I agree that the funding, the FDA partner, it’s all tied on the outcome of this NICE recommendation. Your reasoning for the outcome seems eminently plausible but GDR has seen many false dawns. Is this going to be another? Who knows. Either way Cheek is brave and playing for everything on this news. Time will tell.
Roger has been caught out , and we wont be hearing from him again guys .. he is misleading us all so we will sell up before the rocket launch .
Roger, I read all the available NICE consultation documents and I formed the view that things were not looking too positive for GDR due to the apparent lack of evidence on many issues. This was highlighted throughout the report by many commentators.
However, in full knowledge of all this, NICE have clearly given draft FULL recommendation. NICE didn't have to; they could have reserved judgement until the end of the consultation. The fact that they have given draft FULL recommendation suggests their view things differently and have different criteria - perhaps the POC and speed are overriding objectives.
Given the draft recommendation, it would be extraordinary to reverse the FULL recommendation unless something dramatic indeed occurs. That's obvious, otherwise NICE would have egg on their face. I don't think it's fair to state that GIno was being disingenuous.
Let's see if there's news on Friday, or whether we'll fave to wait to July. I have a feeling the raise and the FDA partnership deal are all riding on this event. GDR must be confident, otherwise why take it to the wire?
Https://twitter.com/genedriveplc/status/1782435768864035249/photo/1
Yes roger pls enlighten us , you have lost a complete fortune and only now have decided to do some research , I believe STUPID HAS BEEN GIVEN A WHOLE NEW MEANING BY YOU ....
THE TRUTH IS YOU SEEKING TO MISLEAD US ALL , Hopping we sell out now , so you get in for even cheaper than it is now , and level up and make a huge profit on friday ...
grow up you silly person .. you have bee caught out lo,l
Ell if you're in here too Metac.nt you'll be losing too very soon. Seems like I'm not the only one who didn't read the report...
I am just LMAO at Rodger the Rabbits latest posts..
He's apparently lost a fortune on GDR? But apparently recently 'bought back in' only to discover he didn't do his DD and now faces losing even more!!!
Tiger, you utter jerk. It’s a public consultation…. Find it on NICE website. You can see every comment made and then the response from the NICE panel. Nothing is hidden and not classified you idiot. Actually read it rather than just saying I’ve read it.
I think Gino was being disingenuous when he said he could see no reason why it wouldn’t granted Full recommendation. When I watched that presentation again the other day the person I was least convinced by was the CFO, who seemed reluctant to say anything and was clearly uncomfortable all the way through it
Excellent post JIMY boy... now would the full recommendation come out first thing on friday from NICE , or would the rocket be launched after hours on friday , so they can open on Monday with a re - rate .. OMG fasten your seat belts ... this is so exciting ...
Roger, regarding "final say"...
NHS have 3 months to allocate funding...
"Funding technology appraisal guidance
The Secretary of State has directed that the NHS is required to provide funding and resources for medicines and treatments recommended by NICE through its technology appraisals work programme. It normally has three months from the date of publication of each technology appraisal guidance to provide funding and resources.
Where it is not possible to acquire the technology or where, perhaps because insufficient trained staff are available, the intervention cannot be applied within the three month period, it can be extended. Extensions are granted by the Secretary of State, on advice from NICE.
The three month funding Direction has been waived or extended for about ten percent of the technology appraisals issued to date. They include surgery to aid weight reduction for people with morbid obesity, home compared with hospital haemodialysis for patients with end-stage renal failure, patienteducation models for diabetes, continuous subcutaneous insulin infusion for diabetes (insulin pumps) and photodynamic therapy for age-related macular degeneration."
The Genedrive POC test is to be used when lab testing isn't available (currently lab testing capacity too low) and in some cases not quick enough.
The Mantara lab test uses a lab in Germany. It's highly unlikely they pose any threat to the Genedrive test for NHS use.
Roger would you mind sharing this classified information with us please .
To clarify I have also read the NICE report , and we do not have any direct comp with any other bio tech , we are the first P O C and if you care to research correctly than you will find once NICE make a draft acceptance for a product , only 1 percent in the history of NICE dont get full approval ... its already approved and the NHS will take it on for use while the other tests are still at the early stages ...
No, I know, but they are clearly anti
And just found this from NICE themselves -
This guidance is advisory and does not have a funding
mandate. NHS England may decide to consider
CYP2C19 genotype testing for inclusion in the National
Genomics Test Directory.
So even if they do approve use of CYP2C19 the NHS will still have the final say on if/where/when the test is used.
Roger, fear not! The Mantara test is not a POC test, it is not a direct competitor.
Inagene Diagnostics also very actively trying to sway opinion against using CYP2C19 suggesting it won't be cost effective long term as there will be newer tests arriving before long that can have much broader scope in what can be tested for.
Gulp....I've spent the last hour and a half reading the NICE consultation documents. I think CYP2C19 is highly unlikely to be given full recommendation. there are numerous other organisations who are clearly anti and suggesting there are better tests eg Mantara Health PGx DNA test which tests for 12 genes rather than just one that GDR test for on reaction to Clopidogrel, and also more cost effective treatments, mainly laboratory testing.
My mood just sank as i read more and more. I think Gino was not being entirely honest when he said in the presentation that he can see 'no reason' why Full recommendation would not be forthcoming. Blimey I've just read the whole thing and I can see there's a lot of opposition. Have to say I was also very disappointed by the lack of submitted evidence from GDR themselves. they only get involved on a handful of issues where as both Mantara and Genomadix are working hard to highlight all and any possible negatives by using the CYP2C19 test.
Flipping heck. I should have read this sooner but now I can see why the share price is going nowhere and yet the consultation period will end this Friday. Bugger Bugger Bugger. I will be amazed if GDR can survive now. If they can't get it to a point where even the NHS will use the test then no will want to buy GDR so there's not even a glimmer of hope that we might see a take over on the cheap. Apologies not to post more positive news. It's grim imv
We'll see on Friday, just sit back and wait.
Good luck!
Roger , many thanks for your thoughts of how you perceive me,,
Fatsen your seat belts .. when this si explodes it will boom ...